首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Chromodomain helicase/ATPase DNA binding protein 1-like protein expression predicts poor prognosis in nasopharyngeal carcinoma
【2h】

Chromodomain helicase/ATPase DNA binding protein 1-like protein expression predicts poor prognosis in nasopharyngeal carcinoma

机译:染色体域解旋酶/ ATP酶DNA结合蛋白1样蛋白表达预测鼻咽癌预后不良

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nasopharyngeal carcinoma (NPC) is a malignancy with a high metastatic ability. Recent studies have implicated the role of chromodomain helicase/ATPase DNA binding protein 1-like (CHD1L) gene as a novel oncogene; however, the functional role of CHD1L in NPC remains unknown. The aim of this study was to evaluate the clinical significance of CHD1L positivity in NPC. CHD1L protein expression was examined by performing western blot analysis of 30 fresh NPC tissues and conducting immunohistochemistry tests of 133 NPC samples between December 1, 2005 and December 1, 2009. The correlations of CHD1L expression status with clinicopathological features and prognosis were investigated. Immunohistochemical analysis showed that 88 of 133 (66.2%) paraffin-embedded NPC biopsies exhibited positive expression of CHD1L, but all non-cancerous nasopharyngeal specimens were negative for CHD1L expression. In addition, positive CHD1L expression was strongly associated with an advanced clinical stage (P=0.016), recurrence (P=0.002) and the metastasis status (P=0.031) of NPC. Kaplan-Meier survival analysis demonstrated that patients with CHD1L-positive NPC had significantly shorter overall survival (P<0.001). Furthermore, the multivariate analysis indicated that CHD1L protein expression was an independent prognostic factor for overall survival (hazard ratio, 7.916; 95% confidence interval, 2.067–16.034; P=0.003) in patients with NPC. These results indicate that CHD1L is a prognostic marker for NPC.
机译:鼻咽癌(NPC)是一种具有高转移能力的恶性肿瘤。最近的研究表明,色域解旋酶/ ATP酶DNA结合蛋白1样(CHD1L)基因作为新型致癌基因的作用。但是,CHD1L在NPC中的功能作用仍然未知。这项研究的目的是评估NPC中CHD1L阳性的临床意义。在2005年12月1日至2009年12月1日之间,通过对30个新鲜NPC组织进行蛋白质印迹分析并对133个NPC样品进行免疫组织化学测试,检测了CHD1L蛋白的表达。免疫组织化学分析显示,在133个石蜡包埋的NPC活检样本中,有88个表现出CHD1L阳性表达,但所有非癌性鼻咽标本均为CHD1L表达阴性。此外,CHD1L阳性表达与NPC的晚期临床阶段(P = 0.016),复发(P = 0.002)和转移状态(P = 0.031)密切相关。 Kaplan-Meier生存分析表明,CHD1L阳性NPC患者的总生存期明显缩短(P <0.001)。此外,多变量分析表明,CHD1L蛋白表达是NPC患者总生存的独立预后因素(危险比,7.916; 95%置信区间,2.067-16.034; P = 0.003)。这些结果表明CHD1L是NPC的预后标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号